PPT-Dual Antiplatelet Therapy (DAPT) Duration

Dilemma Recent Trials And Guidelines For Clinical Practice Dean J Kereiakes MD FACC FSCAI Medical Director The Christ Hospital Heart amp Vascular Center and the Lindner Research Center at The Christ Hospital Cincinnati Ohio. Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . Antiplatelet Guidelines. HEART FAILURE. Working Group: . Alan D. Bell, MD, CCFP; James D. . Douketis. , MD, FRCP. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline . recommendations . Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Juan Felipe Castillo Schrul. Residente Hemodinâmica HCI. Masculino 60 anos. DM2 / DAC. ACTP 2009 => DA em Tto clinico. SGI há 15 dias – internado por Melena / anemia – suspenso AAS. SCA IAMCEST parede inferior com alta carga . Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Evidence-Based Antiplatelet Therapy Across the ACS Spectrum Panelists Program Goals Case Study Case Study (cont) Presenting ECG Guideline for Urgent/Immediate Invasive Strategy (1A Recommendation) An Immediate Invasive Strategy Management of Anticoagulants & Antiplatelet Agents Pre and Post Endoscopy Thomas Savides, M.D. Professor of Clinical Medicine University of California, San Diego Disclosures None Learning Objectives , MD. , PhD. Professor. of Medicine. Medical Director - Cardiovascular . Research. Program. Director – . Interventional. . Cardiology. . Fellowship. University. of Florida . College. of Medicine - Jacksonville. 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD.